[go: up one dir, main page]

ES2134789T3 - Composiciones que contienen melatonina. - Google Patents

Composiciones que contienen melatonina.

Info

Publication number
ES2134789T3
ES2134789T3 ES92303674T ES92303674T ES2134789T3 ES 2134789 T3 ES2134789 T3 ES 2134789T3 ES 92303674 T ES92303674 T ES 92303674T ES 92303674 T ES92303674 T ES 92303674T ES 2134789 T3 ES2134789 T3 ES 2134789T3
Authority
ES
Spain
Prior art keywords
profile
melatonin
diluent
coating
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92303674T
Other languages
English (en)
Inventor
Nava Zisapel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurim Pharmaceuticals 1991 Ltd
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24802245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2134789(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Application granted granted Critical
Publication of ES2134789T3 publication Critical patent/ES2134789T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE PRESENTA UNA FORMULACION FARMACEUTICA DE LIBERACION CONTROLADA QUE COMPRENDE MELATONINA EN COMBINACION CON AL MENOS UN PORTADOR FARMACEUTICO, UN DILUYENTE O UN REVESTIMIENTO, Y QUE ESTA ADAPTADA PARA LIBERAR MELATONINA A LO LARGO DE UN PERIODO DE TIEMPO PREDETERMINADO, DE ACUERDO CON UN PERFIL QUE, TOMANDO EN CUENTA EL PERFIL EXISTENTE, SIMULA EL PERFIL EN EL PLASMA DE UN HUMANO QUE TENGA UN PERFIL DE MELATONINA ENDOGENA NORMAL. LA INVENCION SE REFIERE ADEMAS AL USO EN LA MANUFACTURA DE UN MEDICAMENTO PARA APLICACIONES TERAPEUTICAS EN LA PREVENCION DEL SINDROME DE MUERTE SUBITA EN NIÑOS, DE UNA FORMULACION QUE COMPRENDE MELATONINA EN COMBINACION CON AL MENOS UN DILUYENTE, UN PORTADOR, UN REVESTIMIENTO O UN COADYUVANTE
ES92303674T 1991-05-09 1992-04-23 Composiciones que contienen melatonina. Expired - Lifetime ES2134789T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69771491A 1991-05-09 1991-05-09

Publications (1)

Publication Number Publication Date
ES2134789T3 true ES2134789T3 (es) 1999-10-16

Family

ID=24802245

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92303674T Expired - Lifetime ES2134789T3 (es) 1991-05-09 1992-04-23 Composiciones que contienen melatonina.

Country Status (11)

Country Link
US (2) US5500225A (es)
EP (1) EP0518468B1 (es)
JP (1) JPH072694A (es)
AT (1) ATE181670T1 (es)
DE (2) DE69229490T2 (es)
DK (1) DK0518468T3 (es)
ES (1) ES2134789T3 (es)
GR (1) GR3031257T3 (es)
HK (1) HK1011932A1 (es)
LU (1) LU91378I2 (es)
NL (1) NL300306I1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638963B1 (en) 1990-12-04 2003-10-28 Oregon Health And Science University Methods for treating circadian rhythm disorders
US5707652A (en) * 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
DK0565296T3 (da) * 1992-04-07 1996-12-09 Neurim Pharma 1991 Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
US5385736A (en) * 1993-07-12 1995-01-31 Minnesota Mining And Manufacturing Company Transdermal melatonin delivery system
AU7550994A (en) * 1993-07-26 1995-02-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
PL183148B1 (pl) * 1995-02-01 2002-05-31 Neurim Pharma 1991 Zastosowanie melatoniny do wytwarzania leku do leczenia zależności, nałogu stosowania lub tolerancji na benzodiazepiny oraz zastosowanie melatoniny do wytwarzania leku do zapobiegania zależności, nałogu stosowania lub tolerancji na benzodiazepiny
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
CA2219978C (en) * 1995-06-07 2011-02-01 Ergo Science Incorporated Method for inhibiting neoplastic disease in mammals
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
DE19713141A1 (de) * 1996-03-29 1997-10-30 Labtec Gmbh Transdermales System mit Melatonin
DE19631084A1 (de) 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
EP0951842B1 (en) * 1999-01-20 2002-12-04 N.V. Nutricia Infant formula
MXPA02005783A (es) 2000-01-05 2003-10-14 Neurim Pharma 1991 Metodo y formulacion para el tratamiento de la resistencia a los antihipertensivos y otras afecciones asociadas.
US20020119191A1 (en) * 2000-04-24 2002-08-29 Hitoo Nishino Pharmaceutical or food composition for treatment or prevention of brain edema
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US7365238B2 (en) * 2002-02-19 2008-04-29 The Procter And Gamble Company Absorbent article having a dehydration indicator
KR100501827B1 (ko) * 2002-09-24 2005-07-20 한국화학연구원 다층 코팅법을 이용한 멜라토닌 함유 타게팅 약물 전달 기구
US6703412B1 (en) * 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US7799817B2 (en) * 2004-02-20 2010-09-21 Lifescape Biosciences Inc Compositions and methods for sleep regulation
CA2682200C (en) 2007-03-19 2015-01-13 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
PT2672981T (pt) 2011-02-11 2018-06-21 Zx Pharma Llc Dispersão de partículas de polímero num meio não aquoso
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
FR3000896B1 (fr) 2013-01-14 2016-08-26 Philippe Perovitch Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
AU2013387678B2 (en) 2013-04-23 2015-04-16 Sociétés des Produits Nestlé S.A. Enteric coated multiparticulate controlled release peppermint oil composition and related methods
ES2794374T3 (es) * 2014-10-13 2020-11-18 Worphmed Srl Preparación líquida anhidra de melatonina
CN104546777A (zh) * 2014-12-16 2015-04-29 深圳翰宇药业股份有限公司 美乐托宁缓释组合物的制备方法、美乐托宁缓释片的制备方法
NL2015272B1 (en) * 2015-08-05 2017-05-02 Versailles B V Melatonin formulations and methods for preparation and use.
PT3337462T (pt) 2016-10-31 2020-10-30 Neurim Pharmaceuticals 1991 Ltd Minicomprimidos de melatonina e método de fabrico dos mesmos
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
WO2019038586A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited PHARMACEUTICAL COMPOSITION OF MELATONIN
CN113072479A (zh) * 2021-03-26 2021-07-06 罗田县新普生药业有限公司 一种从褪黑素结晶母液中提取褪黑素的方法
EP4366730A1 (en) 2021-07-05 2024-05-15 Celesta Company LLC Composition for promoting restful sleep and methods of making and using the same
WO2023134856A1 (de) * 2022-01-13 2023-07-20 Paditz Ekkehart Säuglingsnahrung und verfahren zu deren herstellung

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5584503A (en) * 1978-12-19 1980-06-25 Teijin Ltd Preparing cellulose ester based selective permeable membrane
CA1151862A (en) * 1980-01-24 1983-08-16 Thomas J. Fogarty Flexible calibrator
US4855325A (en) * 1985-01-16 1989-08-08 Naftchi Nosrat E Treatment of mammals suffering from damage to the central nervous system
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
AU571922B2 (en) * 1984-01-26 1988-04-28 Schering Agrochemicals Limited Veterinary implants comprising melatonin and derivatives thereof
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
AU601736B2 (en) * 1986-05-23 1990-09-20 Sanofi Sante Nutrition Animale Sa Coated veterinary implants
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
WO1988006009A1 (en) * 1987-02-13 1988-08-25 Maurizio Graziosi System for making atoxic the shoe bottoms
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
GB8727099D0 (en) * 1987-11-19 1987-12-23 Cellena Cell Eng A G Compositions containing melantonin/homologues
FR2630005B1 (fr) * 1988-04-14 1991-11-29 Goupil Jean Jacques Nouveau medicament anti-depresseur contenant du 5-methoxypsoralene
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
JPH03145419A (ja) * 1989-10-31 1991-06-20 Shiseido Co Ltd 紫外線老化の防御薬剤

Also Published As

Publication number Publication date
HK1011932A1 (en) 1999-07-23
EP0518468A1 (en) 1992-12-16
NL300306I1 (nl) 2008-01-02
DE69229490D1 (de) 1999-08-05
GR3031257T3 (en) 1999-12-31
DK0518468T3 (da) 2000-01-31
JPH072694A (ja) 1995-01-06
DE69229490T2 (de) 2000-02-17
LU91378I2 (en) 2008-01-23
ATE181670T1 (de) 1999-07-15
EP0518468B1 (en) 1999-06-30
US5498423A (en) 1996-03-12
US5500225A (en) 1996-03-19
DE122007000073I1 (de) 2008-01-31

Similar Documents

Publication Publication Date Title
ES2134789T3 (es) Composiciones que contienen melatonina.
PT797991E (pt) Formulacao com libertacao prolongada contendo venlafaxina
IT1251544B (it) Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
KR960703009A (ko) 중추유래의 수면성 무호흡증 및 호흡곤란증의 치료를 위한 모다피닐의 사용
DE69404116D1 (de) Mit Zucker überzogene pharmazeutische Dosierungseinheit
DK515489A (da) Dispergerbar laegemiddelformulering
FI895520A0 (fi) Anti-aterosklerotiska diaryl foereningar.
ES2103116T3 (es) Nuevos compuestos bi-aromaticos derivados de amida, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2196167T3 (es) Composicion farmaceutica que contiene propionato de 3-(2,2,2-trimetilhidrazinio) y gamma-butirobetaina para el tratamiento de enfermedades cardiovasculares.
ES2129112T3 (es) Compuestos aromaticos policiclicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
BR0012775A (pt) Comprimido de microgrânulos com baixa dosagem de princìpio ativo contendo um diluente diretamente compressìvel, composição, e, processo de preparação do comprimido
HUT70033A (en) Process for producing synergetic pharmaceutical composition containing calcium channel blocking agent and calcium compound or vitamin d
DK0615439T3 (da) Iburprofenholdigt retard-lægemiddel og dets anvendelse
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
IL98199A0 (en) Pharmaceutical compositions containing a derivative of substituted-l-valyl-l-prolinamide
MX9203900A (es) Composicion farmaceutica que comprende derivados de acido benzimidazolin-2-oxo-1-carboxilico.
DK0457336T3 (da) Ny anvendelse af 4-carbamoyl-1-beta-D-ribofuranosylimidazolium-5-olat
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
IL87867A0 (en) Preparation of pharmaceutical compositions containing a 2,6-diamino-pyridine derivatives
NO910566D0 (no) Farmasoeytisk preparat.
KR950016755A (ko) 간염의 예방 및 치료용 의약조성물
DE69131521D1 (de) Alpha-Ergocryptine enthaltende pharmazeutische Zusammensetzungen mit nervenschützender Wirkung
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.
GR3029898T3 (en) Use of Etofibrate and pharmaceutical compositions containing etofibrate in the treatment of diabetic angio- and retinopathy.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 518468

Country of ref document: ES